Boston Scientific Corp. is enjoying strong revenue growth in all of its business segments. Yesterday the company reported its 2016 third quarter sales, which reached $2.1 billion, thanks to an 11% increase compared to the prior year period.
According to a company release, Boston Scientific reported the following growth:
Business Units
- MedSurg: 15%
- Cardiovascular: 13%
- Rhythm Management: 4%
Geographies
- United States: 11%
- Europe: 6%
- Asia-Pacific, Middle East and Africa: 20%
- Emerging markets: 10%
Other noteworthy developments this quarter include the agreement to acquire EndoChoice Holdings, Inc., a company that provides products to treat gastrointestinal conditions; FDA approval of its EMBLEM MRI Subcutaneous Implantable Defibrillator; CE Mark of the LOTUS Edge Valve System (TAVR); and a $25-million in vestment in VENITI, Inc., a manufacturer of stents for chronic venous insufficiency.
Related Articles
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
“We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry.”
-
It is more important than ever for medical manufacturers to prepare for business interruption due to unexpected damage or natural disasters. From building a recovery team to securing proper insurance, there are many steps device manufacturers can take to recover…
-
Nondisclosure agreements (NDAs) can help protect trade secrets and build a framework for better cooperation and understanding between parties. Following are some key areas to consider when creating an NDA.
